Literature DB >> 33791394

Long-Term Follow-Up of a Portuguese Single-Centre Cohort of Persons with Haemophilia and Hepatitis C Virus Infection.

Tiago Pereira Guedes1, Mónica Garrido1, Ricardo Kuttner Magalhães1, Teresa Moreira1, Marta Rocha1, Luís Maia1, José Manuel Ferreira1, Sara Morais2, Isabel Pedroto1.   

Abstract

INTRODUCTION: Persons with haemophilia (PWH) used to represent a population with a high prevalence of hepatitis C virus (HCV) infection due to the use of contaminated blood products. Although the goals of antiviral therapy are the same as the general population, long real-life follow-up data regarding their outcomes are still scarce. Our aim was to report the outcomes of HCV infection and the results of antiviral therapy in PWH.
METHODS: A retrospective analysis was performed in a single-centre cohort of PWH with positive HCV antibody. Outcomes registered were rate of spontaneous clearance of HCV, sustained virologic response (SVR) achievement, development of end-stage liver disease, and all-cause and liver-related mortality.
RESULTS: Out of 131 PWH, 73 (55.7%) had positive HCV antibody. During a median follow-up time of 22 years, 46 patients (63.9%) developed chronic hepatitis C, of which 16 (34.8%) developed cirrhosis. Treatment was pursued in 34 PWH. Most (n = 32) were first treated with interferon (IFN)-based regimens with SVR rates of 40.6%. Direct-acting antivirals were used in 14 IFN-experienced and 2 naïve patients, with an overall SVR rate of 100%. Overall, 17 patients (23.3%) died during the follow-up, only 4 related to liver disease. Of these, none had achieved SVR.
CONCLUSIONS: We describe the outcomes of a cohort of Portuguese PWH and hepatitis C exposure after two decades of follow-up, with a lower mortality than previously described. Our response rates to HCV treatment were comparable to those in the general population and stress the importance of early treatment.
Copyright © 2020 by S. Karger AG, Basel.

Entities:  

Keywords:  Direct-acting antivirals; End-stage liver disease; Haemophilia A; Haemophilia B; Hepatitis C, chronic

Year:  2020        PMID: 33791394      PMCID: PMC7991614          DOI: 10.1159/000510023

Source DB:  PubMed          Journal:  GE Port J Gastroenterol        ISSN: 2387-1954


  35 in total

1.  Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.

Authors:  G C White; F Rosendaal; L M Aledort; J M Lusher; C Rothschild; J Ingerslev
Journal:  Thromb Haemost       Date:  2001-03       Impact factor: 5.249

2.  Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection.

Authors:  C A M Stedman; R H Hyland; X Ding; P S Pang; J G McHutchison; E J Gane
Journal:  Haemophilia       Date:  2015-08-28       Impact factor: 4.287

Review 3.  Evolving epidemiology of hepatitis C virus.

Authors:  D Lavanchy
Journal:  Clin Microbiol Infect       Date:  2011-02       Impact factor: 8.067

4.  Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials.

Authors:  Zobair M Younossi; Maria Stepanova; Patrick Marcellin; Nezam Afdhal; Kris V Kowdley; Stefan Zeuzem; Sharon L Hunt
Journal:  Hepatology       Date:  2015-03-18       Impact factor: 17.425

5.  Life expectancy of Swedish haemophiliacs, 1831-1980.

Authors:  S A Larsson
Journal:  Br J Haematol       Date:  1985-04       Impact factor: 6.998

6.  The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985.

Authors:  T T Yee; A Griffioen; C A Sabin; G Dusheiko; C A Lee
Journal:  Gut       Date:  2000-12       Impact factor: 23.059

7.  High risk of non-A non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin.

Authors:  P B Kernoff; C A Lee; P Karayiannis; H C Thomas
Journal:  Br J Haematol       Date:  1985-07       Impact factor: 6.998

8.  Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study.

Authors:  I Plug; J G Van Der Bom; M Peters; E P Mauser-Bunschoten; A De Goede-Bolder; L Heijnen; C Smit; J Willemse; F R Rosendaal
Journal:  J Thromb Haemost       Date:  2006-03       Impact factor: 5.824

9.  Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders.

Authors:  Dietje Elisabeth Fransen van de Putte; Michael Makris; Kathelijn Fischer; Thynn Thynn Yee; Lisa Kirk; Karel Johannes van Erpecum; David Patch; Dirk Posthouwer; Eveline Pauline Mauser-Bunschoten
Journal:  J Hepatol       Date:  2013-08-23       Impact factor: 25.083

10.  Long term survival in persons with hemophilia and chronic hepatitis C: 40 year outcomes of a large single center cohort.

Authors:  M Elaine Eyster; Lan Kong; Menghan Li; Ian R Schreibman
Journal:  Am J Hematol       Date:  2016-07-14       Impact factor: 10.047

View more
  2 in total

1.  Implementation of Microelimination Strategy in Eradication of Chronic Hepatitis C Infection in Patients with Hemophilia in the Northern region of Serbia: Is Eradication Possible?

Authors:  Maja Ružić; Natalija Rajić; Milotka Fabri; Ivana Urošević; Marina Dragičević Jojkić; Tomislav Preveden; Maria Pete; Nebojša Rajić
Journal:  Mediterr J Hematol Infect Dis       Date:  2021-09-01       Impact factor: 2.576

Review 2.  Hepatitis C Virus Infections in Patients with Hemophilia: Links, Risks and Management.

Authors:  Anastasia Spanoudaki; Nikolaos Papadopoulos; Eleni-Myrto Trifylli; Evangelos Koustas; Sofia Vasileiadi; Melanie Deutsch
Journal:  J Multidiscip Healthc       Date:  2022-10-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.